Back
ESC Premium Access

Inhibitors of the renin-angiotensin system in diabetic patients with heart failure with preserved ejection fraction treatment: impact of m235t polymorphism of angiotensinogen

Session: Novelties in pathophysiology of heart failure with preserved ejection fraction
Topic: Pharmacotherapy
Speaker: Doctor O. Medentseva (Kharkiv, UA)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Doctor Olena Medentseva

L.T.Malaya Institute of Therapy, Kharkiv (Ukraine)
0 follower

6 more presentations in this session

Heart failure with mid-range (HFmrEF) or recovered (HFrecEF) ejection fraction: differential determinants of transition

Speaker: Doctor A. Mortara (Monza, IT)

Access
Abstract
Slides
Thumbnail

A single factor related to left atrial pressure overload is useful for prognosis in elderly patients with heart failure with preserved ejection fraction: PURSUIT HFpEF study

Speaker: Doctor S. Hoshida (Yao, JP)

Access
Abstract
Slides
Thumbnail

Haemodynamic implications of mitral regurgitation in heart failure with preserved ejection fraction

Speaker: Doctor M. Tamargo Delpon (Madrid, ES)

Access
Abstract
Slides
Thumbnail

Impact of impaired right ventricular strain on the prognosis of HFpEF.

Speaker: Doctor S. Lejeune (Brussels, BE)

Access
Abstract
Slides
Thumbnail

Incremental value of left atrial strain in predicting atrial fibrillation in heart failure with preserved ejection fraction

Speaker: Doctor E. Jasic-Szpak (Wroclaw, PL)

Access
Abstract
Slides
Thumbnail

Access the full session

Novelties in pathophysiology of heart failure with preserved ejection fraction

Speakers: Doctor O. Medentseva, Doctor A. Mortara, Doctor S. Hoshida, Doctor M. Tamargo Delpon, Doctor S. Lejeune...
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb